CURE MITO FOUNDATION

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2018

Legal Domicile

Principal Officer

KASEY WOLEBEN

Phone

6464837073

Tax Period

2025-01-01 to 2025-12-31

CURE MITO FOUNDATION, founded in 2018, is a small nonprofit in the Philanthropy & Grantmaking sector that reported $479K in total revenue in fiscal year 2025. Revenue fell 29% from the prior year — a significant decline worth monitoring. Net assets of $1.1M represent 26 months of operating reserves.

Mission

OUR MISSION IS TO UNITE THE GLOBAL LEIGH SYNDROME COMMUNITY TO ACCELERATE PATIENT-CENTERED RESEARCH, TREATMENTS, AND CURES BY FUNDING RESEARCH AND SUPPORTING COLLABORATION IN LEIGH SYNDROME AND MITOCHONDRIAL DISEASE.

Program Service Accomplishments

Program 1

Expenses: $373,457

RESEARCH FUNDING TO ADVANCE TREATMENTS FOR LEIGH SYNDROME AND MITOCHONDRIAL DISEASE

Program 2

Expenses: $23,203

EDUCATION, OUTREACH, AND ENGAGEMENT ACTIVITIES DESIGNED TO SUPPORT INDIVIDUALS AND FAMILIES AFFECTED BY LEIGH SYNDROME AND TO ELEVATE PATIENT AND CAREGIVER PERSPECTIVES IN RESEARCH AND CARE

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $478,581

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $478,581

Expense Breakdown

Grants Paid $373,457

Salaries & Benefits $65,792

Fundraising Expenses $0

Program Expenses $396,660

Other Expenses $63,139

TOTAL EXPENSES $502,388

Year-over-Year Comparison

	2025	2024	Change
Revenue	$478,581	$674,195	-0.3%
Expenses	$502,388	$334,798	+0.5%
Net Income	$-23,807	$339,397	-1.1%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$60,775

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
KASEY WOLEBEN	EXECUTIVE DIRECTOR	20.00	Officer Highest	$60,775	$0	$60,775
BILL SUZOR	DIRECTOR	1.00	Director	$0	$0	$0
DOUG WOLEBEN	TREASURER	1.00	Officer	$0	$0	$0
JACOB BOGGS	BOARD MEMBER EMERITUS	1.00		$0	$0	$0
COURTNEY BOGGS	SECRETARY	1.00	Officer	$0	$0	$0
SOPHIA ZILBER	VICE PRESIDENT	5.00	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$478,581	$502,388	$1,053,675	$-23,807
2024	$674,195	$334,798	$1,089,878	$339,397
2023	$560,179	$201,463	$750,481	$358,716
2022	$480,537	$215,537	$391,765	$265,000
2022	$480,537	$215,537	$391,765	$265,000